EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) (NCT01186328), a na phase 1 study. The primary outcome is Maximum Tolerated Dose of EZN-3042.

2. Clinical Question

The clinical question was whether a recommended dose of EZN-3042 could be identified for weekly administration with re-induction chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL). The registry record describes EZN-3042 as a survivin mRNA antagonist and frames the phase I study around safety, tolerability, and biological activity. The primary endpoint is the maximum tolerated dose, with the dose recommendation informed by disease response at Day 36 and the toxicity profile assessed until 30 days after study drug discontinuation.

The treatment was studied in a single group rather than against a concurrent control group. The record describes two doses of EZN-3042 before systemic re-induction therapy, which included vincristine, doxorubicin, prednisone, and PEG-asparaginase. It also lists cytarabine, methotrexate, and hydrocortisone among the interventions. The detailed arm description is incomplete, so the full administration schedule is not reported in the registry record.

Six patients enrolled at Dose Level 1. After two patients at that level experienced dose-limiting toxicities, the dose was de-escalated to Dose Level 0. No patients were accrued at Dose Level 0 before study closure. Thus, the record describes a dose-finding question but does not document enrollment or outcome information at the lower dose level sufficient to establish a recommended dose. The secondary outcome concerned decreases in survivin transcript expression after EZN-3042 administration, but its result is not reported in the registry record.

3. Trial Design

NCT01186328 is listed as a phase I study sponsored by the Therapeutic Advances in Childhood Leukemia Consortium. It was a single-group study with no masking and no randomized allocation. The registry status is terminated. The recorded study start date is 2010-08-24, and the primary completion date is 2012-01-10. The reason for termination is not reported in the registry record.

Six patients were enrolled at EZN-3042 Dose Level 1. The record states that two patients at this level experienced dose-limiting toxicities, after which the dose was de-escalated to Dose Level 0. No patients were accrued at Dose Level 0 before study closure. This sequence is consistent with a dose-finding design in which tolerability informs dose escalation or de-escalation, but the registry record does not report a complete decision algorithm, dose amounts, or the detailed rules used to determine dose-limiting toxicity.

The planned treatment combined EZN-3042 with re-induction chemotherapy. The arm description says patients would receive two doses of EZN-3042 before systemic therapy with vincristine, doxorubicin, prednisone, and PEG-asparaginase. Cytarabine, methotrexate, and hydrocortisone are also listed as interventions. The arm description ends before all treatment details are given, so the full regimen and any conditions governing additional treatments are not reported in the registry record.

There is no like-for-like control arm. Consequently, outcomes in this study cannot support a randomized comparison of EZN-3042 with another treatment. The registry record does not report a sample-size justification, detailed statistical plan, interim analysis procedures, or a reason for the study’s closure.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: 6 patients were enrolled at Dose Level 1. Dose level deescalated to Dose level 0 after 2 patients in Dose Level 1 experienced dose limiting toxicities. No patients were accrued on Dose level 0 prior to study closure.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Maximum Tolerated Dose of EZN-3042, measured over 2 months.

The primary endpoint is the maximum tolerated dose of EZN-3042, recorded as a count of participants. The stated objective is to determine the recommended dose when EZN-3042 is administered weekly with re-induction chemotherapy. The dose decision is described as drawing on disease response at Day 36 and toxicity assessed until 30 days after study drug discontinuation. The endpoint timeframe is listed as 2 months.

In general, a phase I dose-finding endpoint is used to guide selection of a dose for further study by weighing tolerability against the study’s other specified considerations. Dose-limiting toxicities are important because they can signal that a dose is not tolerable under the study’s criteria. The registry record reports that two patients at Dose Level 1 experienced dose-limiting toxicities and that the dose was then de-escalated. It does not report the detailed toxicity criteria, the EZN-3042 dose amounts, or a completed maximum-tolerated-dose determination.

The endpoint’s count-based format does not itself convey the clinical severity, timing, duration, or attribution of each toxicity. Those details would be needed to interpret individual events more fully, and they are not reported in the registry record. Because no patients were accrued at Dose Level 0 before closure, the record does not establish how that lower level was tolerated or whether it became the recommended dose.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies a phase I, single-group study with no masking and no randomized allocation. These design features shape what can be learned from the results. A single-group study describes outcomes among participants receiving the study regimen. Without a concurrent comparison group, differences attributable to EZN-3042 cannot be separated from effects of chemotherapy, disease course, or other factors. In general, randomization helps balance measured and unmeasured characteristics between groups; it was not part of this study’s recorded design.

What does a dose-finding endpoint represent?

In general, dose-finding studies use observed toxicity and other protocol-defined information to guide decisions about dose levels. The registry record states that the objective was to determine a recommended weekly dose of EZN-3042 with re-induction chemotherapy. It names disease response at Day 36 and toxicity assessed until 30 days after study drug discontinuation as considerations. It reports that two patients at Dose Level 1 experienced dose-limiting toxicities, prompting de-escalation to Dose Level 0. The detailed dose levels, toxicity definitions, and dose-decision rules are not reported in the registry record.

A maximum tolerated dose is not established merely by observing dose-limiting toxicity at one level. The record also needs adequate information on the relevant dose levels and how participants tolerated them under the study’s criteria. No patients were accrued at Dose Level 0 before closure, so the registry results do not describe tolerability at that level. The record therefore documents a dose adjustment, not a completed dose recommendation.

How should the count-based endpoint be read?

The primary endpoint is recorded as a count of participants and titled maximum tolerated dose of EZN-3042. A count can describe how many participants meet a defined outcome, but it is not a comparative effect estimate by itself. Interpreting it depends on the endpoint definition, observation window, and rules for classifying events. The record specifies an endpoint timeframe of 2 months and describes toxicity assessment through 30 days after study drug discontinuation. It does not provide the full criteria or participant-level event timelines.

What can inferential statistics add?

In general, inferential methods use a sample to quantify uncertainty about a broader population or to compare groups. A confidence interval describes uncertainty around an estimate under the chosen model. A p-value summarizes how compatible the observed data are with a specified null hypothesis and statistical assumptions. Neither is reported among the registry analyses, which are listed as absent. The lack of an inferential result is not evidence of no effect; it means that the registry record does not report such a statistical test or estimate.

The record includes a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. Such calculations are prospective planning illustrations, not observed power and not results from this single-group trial. Equal allocation between two arms does not match the recorded study design. The record does not report a trial-specific sample-size justification or an observed comparative effect to which the illustration could be reliably applied.

Why does over-dispersion matter in general?

In general, over-dispersion occurs when the variability in count data is greater than a statistical model expects. If a model assumes less variability than the data have, uncertainty may be understated and inferential results may appear more precise than warranted. This concept is relevant to some count outcomes, but the registry record does not report a count model, a dispersion estimate, or an analysis addressing over-dispersion. No conclusion about the presence of over-dispersion in this study can be drawn from the posted results.

What does the absence of an analysis mean?

The record lists no analyses. It does not report adjusted models, subgroup analyses, hypothesis tests, confidence intervals, or an analysis population definition. These items are not interchangeable: a participant count can be reported descriptively without an inferential model, while an adjusted estimate requires a stated model and assumptions. Because such analyses are not reported, statistical precision and possible covariate adjustment cannot be evaluated from the registry record.

In general, small studies can be especially sensitive to the outcomes of individual participants. That is a caution about interpretation, not a numerical estimate of uncertainty for this trial. Here, the recorded group size was six, and there was no randomized comparison. The results are therefore best read as a limited descriptive account of the enrolled group and the dose-de-escalation decision, rather than as a definitive comparison or a completed dose-finding result.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists a primary outcome and a secondary outcome concerning a decrease from Day -6 in survivin transcript expression after EZN-3042 administration. It does not report results for the secondary outcome. It also lists two outcome measures, but no analyses are reported. The statistical plan for handling multiple outcomes or multiple tests is not reported in the registry record.

In general, multiplicity arises when several outcomes, time points, subgroups, or statistical tests are examined. Repeated testing can increase the chance of finding an apparently notable result by chance unless the analysis plan accounts for it. No multiplicity adjustment or prespecified hierarchy is reported, so the handling of multiple comparisons cannot be assessed.

Missing-data procedures and analysis populations are not reported in the registry record. The record does not describe how participants with incomplete assessments, early discontinuation, or missing outcome measurements were handled. It also does not specify whether analyses used all enrolled participants, participants who received treatment, or another defined group. These details matter because different inclusion rules can change the interpretation of observed counts.

The reason for termination, any interim analyses, and the final statistical analysis plan are not reported in the registry record. Without those details, it is not possible to assess whether outcome reporting followed a prespecified analysis strategy or how any incomplete follow-up was addressed.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: aspartate aminotransferase increased (16.7%), ggt increased (16.7%), lung infection (16.7%), enterocolitis infectious (16.7%), gastric hemorrhage (16.7%).

For EZN Dose Level 1, the registry record lists six participants at risk for serious adverse events and three affected. It lists six at risk for other adverse events and six affected. Four deaths are also recorded. These are descriptive counts for the enrolled group. They do not establish that study treatment caused an event, and the record does not provide event-level attribution or timing.

The most frequently listed serious adverse event terms are aspartate aminotransferase increased, GGT increased, lung infection, infectious enterocolitis, gastric hemorrhage, and sepsis. Each term is reported as 16.7%. The registry record does not provide further context in these terms about severity grades, duration, resolution, or whether events overlapped within participants. The listed percentages should not be interpreted as evidence about comparative risk because there was no control group.

The two dose-limiting toxicities at Dose Level 1 prompted de-escalation, according to the endpoint description. The registry record does not identify those toxicities in the posted summary, so they cannot be equated with particular serious adverse event terms. Nor does it state whether the four deaths were related to disease, treatment, or another cause. Safety interpretation is therefore limited to the reported counts and terms, without causal conclusions.

12. What the Result Does, and Does Not, Mean

The record documents that six patients enrolled at Dose Level 1 and that two experienced dose-limiting toxicities. The dose was subsequently de-escalated to Dose Level 0, but no patients were accrued at that level before study closure. This supports a narrow description of the study’s dose-finding course: a toxicity-triggered de-escalation occurred, and the lower level was not evaluated in enrolled participants before closure.

Those details do not establish a recommended dose or a maximum tolerated dose. The registry record does not report the detailed dose levels, toxicity criteria, full analysis, or outcomes at Dose Level 0. The primary endpoint’s stated consideration of disease response at Day 36 and toxicity through 30 days after discontinuation does not substitute for a reported final endpoint result.

The study also does not establish whether EZN-3042 changed survivin transcript expression or improved disease response. The secondary outcome is named, but its result is not reported in the registry record. No comparative efficacy result is reported, and the single-group design cannot distinguish the effects of EZN-3042 from the accompanying chemotherapy or other influences.

The adverse event counts and listed serious event terms provide descriptive safety information for the enrolled group. They cannot determine whether treatment caused an event, how risks compare with another regimen, or how frequently an event would occur in a broader population. Four deaths are recorded, but their causes and relationship to treatment are not reported in the registry record.

Accordingly, the posted information is best understood as a limited record of enrollment, dose de-escalation, and adverse event counts. It does not supply a completed dose recommendation, a treatment-effect estimate, or a comparative safety conclusion.

13. Why This Trial Matters Statistically

This study illustrates a central statistical challenge in early-phase research: a dose-finding question depends on accumulated information across dose levels, but the lower level in this study had no accrual before closure. The record identifies a response to dose-limiting toxicities at Dose Level 1, yet does not provide observations at Dose Level 0. Without those observations and the full decision criteria, the dose-finding process cannot yield a documented final recommendation from the registry record.

Its single-group design also highlights the distinction between descriptive evidence and comparative evidence. Counts of adverse events can describe what was recorded among participants, but a control group is needed for a direct comparison of event frequencies under competing treatment strategies. A single-group record cannot isolate the contribution of EZN-3042 when it was combined with re-induction chemotherapy.

The study’s small enrolled group makes transparent reporting particularly important. Individual outcomes are central to the descriptive record, while the absence of an analysis plan, analysis population, and reported inferential estimates limits assessment of precision. In general, estimates based on limited observations can be uncertain; no confidence interval is reported to quantify that uncertainty.

The record also demonstrates why trial status and endpoint completion need context. Termination is recorded, but the reason is not reported. The registry therefore gives an account of what happened at the enrolled dose level without explaining why enrollment stopped or how the intended dose-finding objective was ultimately resolved. These are important statistical interpretation issues, separate from any judgment about the treatments themselves.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The study enrolled six patients, all at Dose Level 1. Although the dose was de-escalated to Dose Level 0 after two patients experienced dose-limiting toxicities, no patients were accrued at Dose Level 0 before closure. As a result, the record does not provide enrolled-patient tolerability observations at the lower dose or a completed dose-finding comparison across levels.

The study had no randomized allocation and a single-group design. There was no like-for-like control group, so the registry data cannot support a direct comparative estimate for EZN-3042 or separate its contribution from the accompanying chemotherapy. The registry status is terminated, but the reason for termination is not reported in the registry record.

The registry does not report the dose amounts, detailed dose-limiting toxicity criteria, complete treatment schedule, or full statistical analysis plan. The arm description is incomplete. Analysis populations, missing-data procedures, multiplicity handling, and interim analysis procedures are also not reported. No analyses are listed, and no confidence intervals or p-values are reported.

The adverse event summary gives counts and selected serious event terms but does not provide event-level timing, severity grades, duration, resolution, or attribution. The four deaths are recorded without a reported cause or relationship to treatment. The secondary outcome result for survivin transcript expression is not reported in the registry record. These gaps limit interpretation of both the dose-finding endpoint and the safety observations.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) — NCT01186328.
• Registry record last updated 2024-02-01; status last verified 2023-05.
• Results first posted 2019-07-24.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01186328 is a phase I, single-group study of EZN-3042 with re-induction chemotherapy in children with relapsed ALL. It enrolled six patients at Dose Level 1. After two patients experienced dose-limiting toxicities, the dose was de-escalated to Dose Level 0; no patients were accrued at that level before study closure. The registry status is terminated, and the reason is not reported.

The primary endpoint was maximum tolerated dose, informed by disease response at Day 36 and toxicity assessment through 30 days after study drug discontinuation. A completed dose recommendation is not reported. For Dose Level 1, the record lists three participants with serious adverse events, six with other adverse events, and four deaths. No analyses are listed, and the result for the secondary survivin transcript outcome is not reported. The single-group design and absence of enrollment at the lower dose limit comparative and dose-finding interpretation.